“How do we do this for not just ten patients? But for 10,000 patients?”
The Australian Financial Review interviewed Emyria CEO Dr Michael Winlo about the current state of psychedelics research and how a potential TGA rescheduling of psychedelic substances might create new research opportunities.
Dr Winlo also discussed Emyria’s leading work in this space with novel MDMA analogues and how rescheduling could pave the way for more real-world studies and help demonstrate safety and efficacy in broader patient populations.
Dr Winlo says, “It’s an important step towards new solutions for the worldwide mental health crisis”.
Read more here (article is behind a paywall): Mental health and psychedelics: Sector races for legitimacy as the Therapeutic Goods Administration takes a cautious stance (http://ow.ly/NJnr50MshAo)